Spanish drugmaker ROVI's 9M revenue rises on strong CDMO, Okedi sales

Overview

• Spain pharmaceutical manufacturer's 9M 2026 operating revenue grew 16% yr/yr

• Net profit for 9M 2026 rose 67% yr/yr

• Company completed acquisition of pharmaceutical plant in Phoenix, Arizona

Outlook

• Company upgrades its 2026 operating revenue guidance

• Expects operating revenue to increase by a mid-to high-single-digit percentage compared with 2025, versus its previous guidance of growth in the low- to mid-single-digit range

• Company says outlook upgrade is mainly the result of the stronger expected growth of the CDMO business

Result Drivers

• CDMO GROWTH - Strong performance in contract development and manufacturing business drove revenue increase

• OKEDI SALES - Sales of Okedi® rose 29% yr/yr, contributing to overall growth

• GROSS MARGIN EXPANSION - Margin growth attributed to CDMO, Okedi®, lower LMWH raw material prices and R&D aid

Company press release: Full Story

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Laboratorios Farmaceuticos Rovi, S.A. is €75.00, about 17.6% above its November 4 closing price of €63.75

• The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 19 three months ago

Reuters Recommended Reads

• Nov 3 - Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis

• Nov 3 - BioNTech's Q3 revenue falls on lower COVID-19 vaccine demand

• Nov 3 - Ireland's Alkermes Q3 revenue beats on LUMRYZ growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)